Form 4: Oric Pharmaceuticals Director Acquires 35,000 Stock Options
SEC Form 4 Filing
Director Steven L. Hoerter acquired 35,000 stock options in Oric Pharmaceuticals on January 2, 2025, according to a Form 4 filing.
Summary
- Steven L. Hoerter, a director of Oric Pharmaceuticals, acquired 35,000 stock options on January 2, 2025.
- The exercise price of these options is $8.26.
- The options vest in monthly installments over a year, starting January 2, 2025, and expire on January 1, 2035.
- Following the transaction, Hoerter directly owns 35,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director can be interpreted as a sign of confidence in the company, but it's a routine transaction.
Positives
- A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.
Stakeholder Impact
- Shareholders may view the director's stock option acquisition as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of transaction: Director Steven L. Hoerter acquired 35,000 stock options. |
| 01/02/2025 | First vesting date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025. |
| 01/01/2035 | Expiration date: Stock options expire on January 1, 2035. |
| 01/06/2025 | Date of filing: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.